Metrics as of 10/17/2026, 08:31 AM (Berlin time), refresh in progress.
Kalaris Therapeutics Stock
Kalaris Therapeutics Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Andrew Oxtoby
- Employees
- 20
- Market cap
- $44 M
- IPO
- 30/07/2020
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular…
Kalaris Therapeutics stock: price history
1D
-8.7%
1W
-15.3%
1M
-37.1%
6M
-68.4%
YTD
-76.3%
1Y
-58.2%
2Y
-99.5%
5Y
-100.0%
10Y
-99.3%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~57% weaker price swings than usual
Ask the agents about Kalaris Therapeutics
Analyst assessment of Kalaris Therapeutics
PRICE TARGET LOW
US$17.00
CONSENSUS
US$17.00
MEDIAN
US$17.00
PRICE TARGET HIGH
US$17.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 13/05/2026
Kalaris Therapeutics stock metrics
P/E
-0.99
P/B
0.83
EV/EBITDA
-0.04
RETURN ON EQUITY
-20.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
33.2%
FLOAT SHARES
7,250,283
AVG. DAILY VOLUME (30D)
79,592
Insider transactions (SEC)
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Kalaris Therapeutics stock
What does Kalaris Therapeutics do?
Kalaris Therapeutics Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Andrew Oxtoby, the company employs around 20 people.
The IPO was on 30/07/2020; the stock trades on NASDAQ under the ticker KLRS.
What do analysts say about Kalaris Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 13/05/2026).
The average price target is US$17.00, ranging from US$17.00 to US$17.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Kalaris Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -57% stronger than usual.
Does Kalaris Therapeutics pay a dividend?
No, Kalaris Therapeutics currently does not pay a dividend.
Which stocks are comparable to Kalaris Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kalaris Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kalaris Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.